BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12893985)

  • 1. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
    Kirchheiner J; Störmer E; Meisel C; Steinbach N; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Aug; 13(8):473-80. PubMed ID: 12893985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
    Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
    Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
    Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
    J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
    Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
    Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
    Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
    Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
    Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
    Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
    Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
    Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
    Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.
    Liu R; Gong C; Tao L; Yang W; Zheng X; Ma P; Ding L
    Eur J Pharm Sci; 2015 Nov; 79():13-9. PubMed ID: 26360837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.
    Werner U; Werner D; Pahl A; Mundkowski R; Gillich M; Brune K
    Biomed Chromatogr; 2002 Feb; 16(1):56-60. PubMed ID: 11816012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
    Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
    Rodrigues AD; Yang Z; Chen C; Pray D; Kim S; Sinz M
    Clin Pharmacol Ther; 2006 Sep; 80(3):298-301; author reply 301-02. PubMed ID: 16952496
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
    Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
    Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
    García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
    Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.